Physician profile
Stacey Clark
NPI 1528098712
$1,962.34
in general payments reported to CMS, 2019-2025
28 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $296 · 2023: $593 · 2024: $540 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $331.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $235.87 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $226.00 | 2023-2025 | |
| Alkermes, INC. | $129.17 | 2021-2024 | Vivitrol, Vivitrol |
| Janssen Pharmaceuticals, INC | $126.35 | 2022-2025 | Spravato |
| Pfizer INC. | $115.60 | 2023-2025 | |
| Glaxosmithkline, LLC. | $86.00 | 2022-2023 | Shingrix, Arexvy |
| Supernus Pharmaceuticals, INC. | $80.01 | 2024 | Qelbree |
| Boston Scientific Corporation | $73.42 | 2025 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $55.41 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $48.89 | 2022 | |
| Baxter Healthcare | $46.54 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amgen INC. | $40.32 | 2021-2023 | Otezla, Repatha |
| Aimmune Therapeutics, INC. | $40.31 | 2024 | |
| Exact Sciences Corporation | $39.23 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $33.37 | 2023-2025 | Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $32.41 | 2021 | |
| Currax Pharmaceuticals LLC | $29.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.48 | 2023 | |
| Inspire Medical Systems, INC. | $25.53 | 2023 | Inspire |
| Amarin Pharma, INC. | $23.70 | 2021 | |
| Genentech USA, INC. | $18.45 | 2021 | |
| Phadia US INC. | $17.46 | 2024 | Immunocap |
| Philips North America LLC | $16.98 | 2022 | |
| Sumitomo Pharma America, INC. | $16.96 | 2024 | Gemtesa |
| Bausch Health US, LLC | $16.88 | 2024 | Wellbutrin, Aplenzin |
| Acella Pharmaceuticals, LLC | $14.59 | 2025 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.